BD Synapsys Informatics Solution with software versions: 4.20, 4.30, 5.10, 5.20 and 5.30- IVD standalone laboratory software solution providing data management and workflow management functionality across locations where clinical diagnostic activities take place. Catalog Number: 444150
Published October 16, 2024 · Recall initiated: September 12, 2024
Summary
FDA records medical device Class II recall Z-0026-2025, published October 16, 2024 and initiated September 12, 2024. Recalling firm: Becton Dickinson & Co.; Status: Ongoing; Reported quantity: 162 units; Lot: UDI-DI: 00382904441500 Software versions: 4.20, 4.30, 5.10, 5.20 and 5.30. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Synapsys software versions 4.20, 4.30, 5.10, 5.20, or 5.30 and utilizing the in-line breakpoint feature, an error is occurring where BD Synapsys will incorrectly display breakpoints for organisms that do not have defined breakpoints in CLSI or EUCAST. This occurs when the identified organism is included in the same interpretive group as a species for which there is a specific breakpoint. May result in either a false susceptible or false resistant result. A false susceptible result can cause inadequate or incomplete antibiotic treatment due to the use of an ineffective antibiotic, and a false resistant result may limit access to a preferred antibiotic regimen with possible elongation of therapy
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Becton Dickinson & Co.
- Distributor
- Nationwide Foreign: Australia, New Zealand, Singapore, Hong Kong, Taiwan, Japan, Austria, Belgium, Denmark, France, Germany, Italy, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland, United Kingdom, Russia, Saudi Arabia, South Africa, Canada, Mexico, China
- Lot
- UDI-DI: 00382904441500 Software versions: 4.20, 4.30, 5.10, 5.20 and 5.30
- Risk classification
- Class II
- Area (FDA)
- device
- Country
- United States
Related recalls
- FDABD Phoenix Panel NMIC-312. Catalog Number: 449082.October 21, 2026
- FDABD Phoenix Panel NMIC-306. Catalog Number: 449292.October 21, 2026
- FDABD GasPak EZ CO2 Pouch System. Catalog Number: 260684. for microbiologic useMay 6, 2026
- FDABD GasPak EZ Campy Pouch System. Catalog Number: 260685. for microbiologic useMay 6, 2026
- FDABeckman Coulter Dxl 9000 Access Immunoassay Analyzer, REF #C11137. An in vitro diagnostic device used for theOctober 16, 2024
- FDAAligned Medical Tonsil Tray REF AMS9300A that contains the Cardinal Health Salem Sump PVC tubes. ProductOctober 16, 2024
Questions about this recall
Was BD Synapsys Informatics Solution with software versions: 4.20, 4.30, 5.10, 5.20 and 5.30- IVD standalone laboratory software solution providing data management and workflow management functionality across locations where clinical diagnostic activities take place. Catalog Number: 444150 recalled?
Yes. FDA published recall Z-0026-2025 on October 16, 2024. Reported hazard: Synapsys software versions 4.20, 4.30, 5.10, 5.20, or 5.30 and utilizing the in-line breakpoint feature, an error is occurring where BD Synapsys will incorrectly display breakpoints for organisms that do not have defined breakpoints in CLSI or EUCAST. This occurs when the identified organism is included in the same interpretive group as a species for which there is a specific breakpoint. May result in either a false susceptible or false resistant result. A false susceptible result can cause inadequate or incomplete antibiotic treatment due to the use of an ineffective antibiotic, and a false resistant result may limit access to a preferred antibiotic regimen with possible elongation of therapy
What should I do if I have this product?
Voluntary: Firm initiated · Letter